These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1092 related articles for article (PubMed ID: 18852562)

  • 1. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.
    Pei JJ; Sjögren M; Winblad B
    Curr Opin Psychiatry; 2008 Nov; 21(6):555-61. PubMed ID: 18852562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dissection of the neurofibrillary lesions of Alzheimer's disease.
    Goedert M
    Arzneimittelforschung; 1995 Mar; 45(3A):403-9. PubMed ID: 7763334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSK-3 inhibitors for Alzheimer's disease.
    Avila J; Hernández F
    Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
    Hardy J; Selkoe DJ
    Science; 2002 Jul; 297(5580):353-6. PubMed ID: 12130773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurofibrillary tangles and early modification of the neuronal cytoskeleton in Alzheimer's disease and in experimental models].
    Brion JP
    Bull Mem Acad R Med Belg; 1999; 154(6 Pt 2):287-94. PubMed ID: 10992876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
    Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
    J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo.
    Zilka N; Filipcik P; Koson P; Fialova L; Skrabana R; Zilkova M; Rolkova G; Kontsekova E; Novak M
    FEBS Lett; 2006 Jun; 580(15):3582-8. PubMed ID: 16753151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
    Walton JR
    J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of neurofibrillary tangles in Alzheimer disease.
    Brion JP
    Acta Neurol Belg; 1998 Jun; 98(2):165-74. PubMed ID: 9686275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrastructural aspects of neurofibrillary tangle formation in aging and Alzheimer's disease.
    Gómez-Ramos P; Morán MA
    Microsc Res Tech; 1998 Oct; 43(1):49-58. PubMed ID: 9829459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.
    van de Nes JA; Nafe R; Schlote W
    Brain Res; 2008 Jun; 1213():152-65. PubMed ID: 18455153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease.
    Savory J; Huang Y; Wills MR; Herman MM
    Neurotoxicology; 1998 Apr; 19(2):209-14. PubMed ID: 9553957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of protein kinase B in Alzheimer's neurofibrillary pathology.
    Pei JJ; Khatoon S; An WL; Nordlinder M; Tanaka T; Braak H; Tsujio I; Takeda M; Alafuzoff I; Winblad B; Cowburn RF; Grundke-Iqbal I; Iqbal K
    Acta Neuropathol; 2003 Apr; 105(4):381-92. PubMed ID: 12624792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transgenic zebrafish model of neurodegeneration.
    Tomasiewicz HG; Flaherty DB; Soria JP; Wood JG
    J Neurosci Res; 2002 Dec; 70(6):734-45. PubMed ID: 12444595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.
    Buerger K; Ewers M; Pirttilä T; Zinkowski R; Alafuzoff I; Teipel SJ; DeBernardis J; Kerkman D; McCulloch C; Soininen H; Hampel H
    Brain; 2006 Nov; 129(Pt 11):3035-41. PubMed ID: 17012293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
    Wang JZ; Grundke-Iqbal I; Iqbal K
    Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of cell division cycle (cdc) 2 kinase in neurons with early stage Alzheimer's disease neurofibrillary degeneration.
    Pei JJ; Braak H; Gong CX; Grundke-Iqbal I; Iqbal K; Winblad B; Cowburn RF
    Acta Neuropathol; 2002 Oct; 104(4):369-76. PubMed ID: 12200623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.